Lisata Therapeutics highlights iRGD cyclic peptide product candidate data

Lisata Therapeutics (LSTA) highlighted preclinical data as announced by Lisata’s licensing partner, Catalent, at the 16th Annual World ADC San Diego Conference, held November 3-6. Catalent’s presentation included data demonstrating the impact of incorporating Lisata’s proprietary iRGD cyclic peptide product candidate, certepetide, and its analogs as a payload in Catalent’s SMARTag antibody-drug conjugate technology platform. Specifically, Catalent reported preclinical results showing that using certepetide as a non-cytotoxic ADC payload not only improved ADC efficacy but also broadened the distribution of the cytotoxic payload within the tumor microenvironment. A summary of these results can be found here in the company’s latest corporate presentation. “This data is encouraging as it reinforces the large and growing body of evidence indicating that certepetide can enhance the targeting, penetration, and effectiveness of therapeutic agents – in this case, ADCs – in which it is chemically incorporated or co-administered,” stated Kristen Buck, Executive Vice President of Research and Development and Chief Medical Officer of Lisata. “ADCs are one of the fastest growing and most exciting therapeutic categories in drug development. These results underscore our belief in the value of our licensing partnership with Catalent and supports our strategy of leveraging certepetide’s unique mechanism to enhance the therapeutic potential across all modalities of treatments.”